Scientists using cancer registry data identified a subset of patients with early-stage melanoma with almost no melanoma-related deaths. The study “Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with very low melanoma mortality,” published in Cancer, may help clinicians determine which patients have a low risk of death from melanoma after removal of the growth, according to the researchers.
2022
DREAMSeq Trial Clarifies Treatment Sequencing in BRAF V600–Mutant Melanoma
Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations, according to Andrew L. Pecora, MD, FACP, CPE, who explained that patients tend to live longer when receiving ipilimumab (Yervoy) plus nivolumab (Opdizvo) before receiving dabrafenib (Tafinlar) plus trametinib (Mekinist).
Immune Reprogramming Inhibits Tumor Progression in Melanoma Model
A series of experimental studies by UK researchers has shown that miniature spherical particles called protocells loaded with a cargo that inhibits microRNA-223 (miR223) can alter interactions between immune cells and cancer cells and ultimately reduce tumor burden.
Pitt scientists solve the mystery of how melanoma tumors control their mortality
Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality.